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Introduction: 
Mortality from chronic kidney disease (CKD) is increasing Worldwide and is currently ranked 14th 
commonest cause of death1. Most patients die from cardiovascular disease and management of 
cardiovascular risk is the key to prevent both death and decline of renal function to the point of end 
stage renal disease (ESRD). In the UK 14% of men and 13% women have CKD, the majority being 
managed in primary care. In 2014, National Institute for Clinical Excellence (NICE) introduced 
guidance to help General Practitioners (GP) manage patients with CKD, focussing on cardiovascular 
risk and prevention of late referral of patients likely to require renal replacement therapy2 
This study examined the management of cardiovascular risk and timeliness of referral in all new GP 
referrals to the renal clinic in 2012, and again in 2016, two years after the introduction of NICE CKD 
guidance in 2014. The study was aimed at determining the impact of the updated CKD guidance on 
CKD/cardiovascular risks optimisation and the timeliness of referral from the primary care 
Methods: 
All new GP referrals to the Regional Renal Service in 2012 and 2016 were analyzed. Data were 
collected on patient age, CKD stage and estimated Glomerular Filtration Rate at referral (eGFR), 
renal imaging pre-referral, blood pressure (BP), smoking, body mass index (BMI), glycated 
haemoglobin (HbA1C) (in diabetic patients), and lipid assessment.  
Chi-square analyses were performed using IBM SPSS Statistics version 24. A p value of less than 0.05 
was considered significant. 
Results: 
A total of 486 new GP referrals were received in 2012, compared to 574 in 2016. Data completion 
was 100% for renal imaging pre-referral; blood pressure; BMI; diabetic status; and, lipid assessment 
at referral. The distribution of eGFR of the referred patients is shown in Figure 2. 2 patients in both 
cohorts did not have eGFR/renal stage assessments due to age (< 18 years), and 1 patient in the 
2016 cohort refused blood testing.  
Nearly one third of referrals in 2012 (29.01%) and one fourth in 2016 (24.39%) were aged >80years 
(see Figure 1). 27.8% in 2012 and 30.7% in 2016 of referrals were diabetic. Of the patients with 
diabetes, 60/134 (44.8%) in 2012, and 82/176 (46.6%) in 2016 had HbA1c of greater than 58 
mmol/mol. With 11/134 (8.2%) of diabetic patients in 2012, and 13/176 (7.4%) diabetic patients in 
2016 having HbA1c greater than 86 mmol/mol. HbA1c was not measured in 1 of the 2012 diabetic 
patients. 
In 2012, 167 patients had a systolic blood pressure (SBP) less than 140mmHg compared to 245 in 
2016. 402/486 (82.7%) patients referred in 2012 and 509/573 (88.8%) patients referred in 2016 had 
cholesterol levels checked. Of those tested, 14.9% patients in 2012, and 15.9% in 2016 had a serum 
total cholesterol of 6.3 mmol/L or greater. 
The proportion of obese patients referred shown in Figure 3. 11.7% (2012) and 12.6% (2016) of 
referred patients were current smokers at the time of referral. Pre-referral, Renal Ultrasound was 
done only in 206 of 438 patients in 2012 and 252 of 529 patients in 2016. 48 in 2012 and 45 in 2016 
did not require Renal imaging.  
The change in the proportion of cardiovascular risk factors post NICE guidelines is shown in Table 1. 
Post NICE guidelines there has been an 18% increase in GP referrals. Although the number of 
smokers and obese patients in the referred population have not improved. BP control has 
significantly improved post-NICE (p 0.006 for SBP control) and significantly more patients have had 
cholesterol levels checked (p 0.004).  Post NICE guidelines, although significantly fewer Stage 4 and 5 
CKD patients are being referred (p<0.001), there is no statistically significant improvement in late 
CKD referrals (eGFR <20ml/min/1.73m2,. p=0.272) 
 
Discussion: 
Chronic kidney disease is associated with an increased risk of cardiovascular disease and related 
mortality 3,4,5. Impaired kidney function and raised concentrations of albumin in urine also increase 
the risk of cardiovascular disease by two to four times6 and are independent predictors of mortality 
risk4. Stroke risk also increases linearly and additively with declining GFR and increasing 
albuminuria8. 
The prevalence of CKD stages 3-5 increases with age especially in those above 80 years of age9. 
Among patients of all ages, there was an inverse association between eGFR and the proportion of 
deaths from a cardiovascular cause6,8. However, among those with comparable levels of eGFR, older 
patients are more likely to die than reaching ESRD requiring renal replacement therapy10. 
High BMI is a common, strong, potentially modifiable and an independent risk factor for CKD 
progression and death11,12. A meta-analysis concluded from smaller, short-duration studies in 
patients with CKD that, nonsurgical weight loss interventions reduce proteinuria and BP and seem to 
prevent further decline in renal function13.  
Poorly controlled diabetes is associated with greater risk of microvascular complications in both 
Type1 and Type2 diabetics14,15. Diabetes is now the most common cause of ESRD in developed 
countries and diabetic patients are more likely to require dialysis and less likely to be transplanted16.  
Hypertension is a well-established risk factor for cardiovascular disease (CVD) and a major promoter 
of CKD progression in both diabetic and nondiabetic kidney disease17,18. The reduction in BP 
significantly reduces the risk of death and cardiovascular disease in general population19-22and is 
markedly reno-protective in CKD population, regardless of the type of drug administered23-26. NICE 
recommends aiming a systolic BP of less than 140mmHg in CKD patients and less than 130mmHg in 
CKD patients with diabetes and or proteinuria.  
Reduction of LDL, cholesterol with medications safely reduced the incidence of major atherosclerotic 
events in patients with less advanced chronic kidney disease27. 
Risk of death is higher in renal failure patients who are current smokers compared to non-smokers 
and the risk increases with increase in number of daily cigarettes28. 
 
Conclusion: 
GPs are better in optimising Blood pressure control and screening for hyperlipidaemia in the CKD 
population. Management of other cardiovascular risk factors in CKD patients need further 
optimisation pre-referral with attention to diabetes management and life style modifications such as 
smoking cessation and weight reduction. Early referrals to Nephrology should be considered for 
patients, who meets referral criteria as per NICE CKD guidelines for better patient prognosis and late 
CKD referrals to be avoided where possible. 
 
 
 Figure 1: Distribution of new patients referred to renal clinic from GPs based on age before (n = 486) 

























Age  Years 
2012
2016
Table 1: Comparison of cardiovascular risk factors in GP referred patients pre- (n= 486) and post-









Chi square p-value 
stage 4 & 5 patients 33.9 23.5 14.024 < 0.001 
eGFR < 20 7.9 6.1 1.206 0.272 
Ultrasound pre 
referral 
47.0 47.5 0.025 0.875 
SBP > 140 65.6 57.4 7.483 0.006 
DBP > 90 26.3 19.0 8.100 0.004 
Cholesterol tested 82.7 88.8 8.178 0.004 
High BMI 34.8 40.8 4.102 0.043 
Diabetic 27.8 30.7 1.094 0.296 






Figure 2: Distribution of referred patients based on eGFR (ml/min/1.73m2) at the time of referral 































Figure 3: Distribution of patients based on Body mass index (kg/m2) before and after the 
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